奥希替尼引起的心脏功能障碍 - Suppr

Suppr

超能文献

Cardiac Dysfunction Caused by Osimertinib.

作者信息

Oyakawa Takuya, Nakashima Kazuhisa, Naito Tateaki

机构信息

Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan.

出版信息

J Thorac Oncol. 2017 Oct;12(10):e159-e160. doi: 10.1016/j.jtho.2017.05.016.

DOI:10.1016/j.jtho.2017.05.016

PMID:28939147

Abstract

摘要

相似文献

Cardiac Dysfunction Caused by Osimertinib.奥希替尼引起的心脏功能障碍

J Thorac Oncol. 2017 Oct;12(10):e159-e160. doi: 10.1016/j.jtho.2017.05.016.

Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity.奥希替尼严重诱导肝毒性后成功再次使用奥希替尼治疗

J Thorac Oncol. 2017 May;12(5):e61-e63. doi: 10.1016/j.jtho.2017.01.026. Epub 2017 Mar 11.

Osimertinib-Induced Interstitial Lung Disease Presenting as Eosinophilic Pneumonia.奥希替尼诱发的间质性肺病表现为嗜酸性粒细胞性肺炎。

J Thorac Oncol. 2017 Aug;12(8):e118-e120. doi: 10.1016/j.jtho.2017.03.022.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.奥希替尼诱导的间质性肺病后，T790M 突变型非小细胞肺癌患者成功再次使用奥希替尼治疗。

J Thorac Oncol. 2017 May;12(5):e59-e61. doi: 10.1016/j.jtho.2017.01.027.

High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy.在接受过nivolumab治疗的患者中实际使用奥希替尼后，间质性肺疾病的发生率较高。

Ann Oncol. 2017 Mar 1;28(3):669-670. doi: 10.1093/annonc/mdw647.

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC).奥希替尼治疗表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）期间的充血性心力衰竭

Intern Med. 2017 Aug 15;56(16):2195-2197. doi: 10.2169/internalmedicine.8344-16. Epub 2017 Aug 1.

Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.新型非小细胞肺癌肿瘤疗法在接受新一代酪氨酸激酶抑制剂治疗患者中的心血管安全性

Kardiol Pol. 2018;76(3):670. doi: 10.5603/KP.2018.0061.

Heterogeneity-based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report.奥希替尼（AZD9291）耐药的基于异质性、多种机制：病例报告。

Thorac Cancer. 2018 Apr;9(4):498-501. doi: 10.1111/1759-7714.12596. Epub 2018 Feb 7.

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.奥希替尼治疗表皮生长因子受体酪氨酸激酶抑制剂耐药的非小细胞肺癌患者时发生严重再生障碍性贫血

J Thorac Oncol. 2017 May;12(5):e46-e47. doi: 10.1016/j.jtho.2016.12.023.

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease.奥希替尼诱导的间质性肺疾病后采用类固醇治疗成功再次使用奥希替尼

Intern Med. 2018 Jan 1;57(1):91-95. doi: 10.2169/internalmedicine.8947-17. Epub 2017 Oct 16.

引用本文的文献

Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in mutated non-small cell lung cancer: systematic review and network meta-analysis.突变型非小细胞肺癌中与表皮生长因子受体酪氨酸激酶抑制剂相关的心血管不良事件：系统评价和网状Meta分析

BMJ. 2025 Sep 2;390:e082834. doi: 10.1136/bmj-2024-082834.

Real-World Data on Osimertinib-Associated Cardiac Toxicity.奥希替尼相关心脏毒性的真实世界数据。

J Clin Med. 2025 Mar 5;14(5):1754. doi: 10.3390/jcm14051754.

Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer.心脏问题：与致癌基因成瘾性非小细胞肺癌靶向治疗相关的心脏毒性

Int J Mol Sci. 2025 Jan 10;26(2):554. doi: 10.3390/ijms26020554.

Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond.非小细胞肺癌治疗及其他领域中表皮生长因子受体酪氨酸激酶抑制剂心脏毒性认识的进展

Front Pharmacol. 2024 Aug 15;15:1404692. doi: 10.3389/fphar.2024.1404692. eCollection 2024.

EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）诱导的非小细胞肺癌心脏毒性：发生率、评估及监测

Front Oncol. 2024 Jun 24;14:1426796. doi: 10.3389/fonc.2024.1426796. eCollection 2024.

Osimertinib-induced biventricular cardiomyopathy with abnormal cardiac MRI findings: a case report.奥希替尼诱发的双心室心肌病伴心脏磁共振成像异常表现：一例报告

Cardiooncology. 2023 Oct 31;9(1):38. doi: 10.1186/s40959-023-00190-1.

Osimertinib induced adverse cardiac events: a case report.奥希替尼诱发的不良心脏事件：一例报告

J Geriatr Cardiol. 2023 Sep 28;20(9):702-706. doi: 10.26599/1671-5411.2023.09.006.

Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels.急性奥希替尼暴露通过同步抑制心脏离子通道电流诱导心电变化。

Front Pharmacol. 2023 May 30;14:1177003. doi: 10.3389/fphar.2023.1177003. eCollection 2023.

Successful neoadjuvant treatment of EGFR exon 19 deletion combined with TP53 mutation in non-small cell lung cancer using aumolertinib after osimertinib-induced myocardial damage: a case report and literature review.奥希替尼诱导心肌损伤后使用阿美替尼成功治疗 EGFR 外显子 19 缺失合并 TP53 突变的非小细胞肺癌：一例病例报告及文献复习。

Anticancer Drugs. 2023 Sep 1;34(8):954-961. doi: 10.1097/CAD.0000000000001496. Epub 2023 Jan 4.

Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology.心脏肿瘤学：机制、药物组合与逆向心脏肿瘤学。

Int J Mol Sci. 2022 Sep 13;23(18):10617. doi: 10.3390/ijms231810617.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验